These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
310 related items for PubMed ID: 18630457
21. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G. Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813 [Abstract] [Full Text] [Related]
22. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531 [Abstract] [Full Text] [Related]
23. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F. Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [Abstract] [Full Text] [Related]
24. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619 [Abstract] [Full Text] [Related]
25. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958 [Abstract] [Full Text] [Related]
26. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP. J Support Oncol; 2003 Sep; 1(2):131-8. PubMed ID: 15352656 [Abstract] [Full Text] [Related]
27. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A. Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062 [Abstract] [Full Text] [Related]
30. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia. Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K. Curr Med Res Opin; 2007 Jun; 23(6):1387-401. PubMed ID: 17559735 [Abstract] [Full Text] [Related]
31. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A, RADAR Study Group. Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513 [Abstract] [Full Text] [Related]
32. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642 [Abstract] [Full Text] [Related]
33. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa]. Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC. Nefrologia; 2004 Oct; 24(1):54-9. PubMed ID: 15083958 [Abstract] [Full Text] [Related]
34. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P. J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537 [Abstract] [Full Text] [Related]
36. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G. Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841 [Abstract] [Full Text] [Related]
37. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Mel JR, Salar A, Rodríguez CA, Alegre A, González A, Cassinello J, Montesinos J, Gasquet JA, Sánchez J, Saigí E, AMG-DAR-2002-01 Study Group. Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103 [Abstract] [Full Text] [Related]
38. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. Chang J, Couture F, Young S, McWatters KL, Lau CY. J Clin Oncol; 2005 Apr 20; 23(12):2597-605. PubMed ID: 15452188 [Abstract] [Full Text] [Related]
39. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ. Am J Kidney Dis; 2002 Jul 20; 40(1):110-8. PubMed ID: 12087568 [Abstract] [Full Text] [Related]